Coherus Confirms Filing Plans For Ranibizumab And Bevacizumab
Both Biosimilar Filings Have Experienced Delays
Coherus BioSciences aims to have four biosimilars on the market by 2023, including ranibizumab and bevacizumab for which it has provided updated timelines for planned US Food and Drug Administration filings.
You may also be interested in...
In June, the $6bn Organon business, including a healthy biosimilars operation, will begin trading, while Coherus BioSciences aims to file for biosimilar Lucentis with partners Formycon and Bioeq.
Swedish developer Xbrane Biopharma has identified a timeline to turn its cash flows positive, with plans to roll-out biosimilar Lucentis next year.
Samsung Bioepis has been tight-lipped on the potential to win approval for its SB11 biosimilar ranibizumab product this year, though new similarity data is a further positive omen for the Korea-based biosimilar player.